scholarly journals Usefulness of C-Reactive Protein to High-Molecular-Weight Adiponectin Ratio to Predict Insulin Resistance and Metabolic Syndrome in Japanese Men

2010 ◽  
Vol 17 (9) ◽  
pp. 944-952 ◽  
Author(s):  
Yoshifumi Saisho ◽  
Hiroshi Hirose ◽  
Yoshie Seino ◽  
Ikuo Saito ◽  
Hiroshi Itoh
Keyword(s):  
Insulin Resistance ◽  
Metabolic Syndrome ◽  
Molecular Weight ◽  
High Molecular Weight ◽  
C Reactive Protein ◽  
High Molecular Weight Adiponectin ◽  
Japanese Men ◽  
Reactive Protein

scholarly journals Treatment of Androgen Excess in Adolescent Girls: Ethinylestradiol-Cyproteroneacetate Versus Low-Dose Pioglitazone-Flutamide-Metformin

2011 ◽  
Vol 96 (11) ◽  
pp. 3361-3366 ◽  
Author(s):  
Lourdes Ibáñez ◽  
Marta Diaz ◽  
Giorgia Sebastiani ◽  
David Sánchez-Infantes ◽  
Cristina Salvador ◽  
...  
Keyword(s):  
Molecular Weight ◽  
High Molecular Weight ◽  
Adolescent Girls ◽  
Low Dose ◽  
Intima Media Thickness ◽  
Carotid Intima Media Thickness ◽  
C Reactive Protein ◽  
Androgen Excess ◽  
High Molecular Weight Adiponectin ◽  
Reactive Protein

Abstract Objective: The aim was to perform a first comparison between the effects of a classic therapy and those of a novel treatment for androgen excess in adolescent girls. Design and Setting: We conducted a randomized, open-labeled trial at a university hospital. Participants: Thirty-four adolescents with hyperinsulinemic androgen excess and without risk of pregnancy participated in the study. Interventions: Ethinyl estradiol-cyproterone acetate (EE-CA) vs. a low-dose combination of pioglitazone, flutamide, and metformin (PioFluMet) was administered for 6 months. Main Outcome Measures: We assessed hirsutism and acne scores; androgen excess; fasting insulin, lipid profile, C-reactive protein, high molecular-weight adiponectin, leptin, follistatin; carotid intima-media thickness; body composition (absorptiometry); and abdominal fat partitioning (magnetic resonance imaging). Results: EE-CA and PioFluMet attenuated the androgen excess comparably but had divergent effects on fasting insulinemia; on circulating cholesterol, triglycerides, C-reactive protein, high molecular-weight adiponectin, leptin, and follistatin; on carotid intima-media thickness; on lean mass; and on abdominal, visceral, and hepatic fat, with all these divergences pointing to a healthier condition on low-dose PioFluMet. Conclusion: Low-dose PioFluMet compared favorably to EE-CA in adolescents with androgen excess and without pregnancy risk. The efficacy and safety of low-dose PioFluMet remain to be studied over a longer term and in larger cohorts.

scholarly journals Reduced High-Molecular-Weight Adiponectin and Elevated High-Sensitivity C-Reactive Protein Are Synergistic Risk Factors for Metabolic Syndrome in a Large-Scale Middle-Aged to Elderly Population: the Shimanami Health Promoting Program Study

2008 ◽  
Vol 93 (3) ◽  
pp. 715-722 ◽  
Author(s):  
Yasuharu Tabara ◽  
Haruhiko Osawa ◽  
Ryuichi Kawamoto ◽  
Rieko Tachibana-Iimori ◽  
Miyuki Yamamoto ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Molecular Weight ◽  
High Molecular Weight ◽  
Metabolic Disorders ◽  
High Sensitivity ◽  
Community Dwelling ◽  
C Reactive Protein ◽  
Middle Aged ◽  
Reactive Protein ◽  
Hmw Adiponectin

Abstract Objective: In Western countries, one of the most important modifiable targets for the prevention of cardiovascular diseases is metabolic syndrome. Adiponectin is an adipose tissue-specific plasma protein that inversely associates with metabolic syndrome. Among several molecular isoforms, high-molecular-weight (HMW) complex is considered the active form. Increased serum high-sensitivity C-reactive protein (hsCRP) concentration also associates with metabolic syndrome, and adiponectin could modulate plasma C-reactive protein levels. Here, through cross-sectional investigation, we investigated whether reduced HMW adiponectin and increased hsCRP levels in plasma are synergistically associated with metabolic syndrome. Measurement of HMW complex of adiponectin is one of the novelties of this study. Design: We analyzed 1845 community-dwelling middle-aged to elderly subjects (62 ± 13 yr). Plasma HMW adiponectin levels were measured by ELISA. Clinical parameters were obtained from the subjects’ personal health records, evaluated at their annual medical check-up. Results: Each component of metabolic syndrome, except for raised blood pressure, showed significantly lower plasma HMW adiponectin concentrations for both men and women (P < 0.001). In contrast, plasma hsCRP levels were significantly higher in subjects with metabolic disorders (P < 0.001). After adjusting for other confounding factors, HMW adiponectin [log normalized, odds ratio 0.084 (95% confidence interval 0.050–0.142), P < 0.001] and hsCRP [3.009 (2.175–4.163), P < 0.001] were identified as independent determinants of metabolic syndrome. In addition to the direct associations, we also observed a synergistic effect between these two molecules (F = 11.8, P < 0.001). Conclusions: Reduced HMW adiponectin and elevated hsCRP are synergistically associated with the accumulation of metabolic disorders. The combination of these markers would be useful for identifying at-risk populations.

scholarly journals TNF-α Antagonism with Etanercept Decreases Glucose and Increases the Proportion of High Molecular Weight Adiponectin in Obese Subjects with Features of the Metabolic Syndrome

2011 ◽  
Vol 96 (1) ◽  
pp. E146-E150 ◽  
Author(s):  
Takara L. Stanley ◽  
Markella V. Zanni ◽  
Stine Johnsen ◽  
Sarah Rasheed ◽  
Hideo Makimura ◽  
...  
Keyword(s):  
Molecular Weight ◽  
High Molecular Weight ◽  
Glucose Homeostasis ◽  
Fasting Glucose ◽  
C Reactive Protein ◽  
High Molecular Weight Adiponectin ◽  
Reactive Protein ◽  
Total Adiponectin ◽  
Tnf Α ◽  
Obese Subjects

Context and Objective: Obesity is associated with activation of the TNF-α system, increased inflammatory markers, and insulin resistance. Although studies in rodents suggest that attenuation of TNF activity improves glucose homeostasis, the effect of prolonged inhibition of TNF-α with etanercept on inflammation and glucose homeostasis in a human model of obesity is not known. Design and Participants: Forty obese subjects with features of metabolic syndrome were randomized to etanercept or placebo, 50 mg twice weekly for 3 months, followed by 50 mg once weekly for 3 months. Outcome Measures: Subjects underwent oral glucose tolerance testing and measurement of serum inflammatory biomarkers and adipokines. Subcutaneous fat biopsy was performed in a subset for measurement of adipokine and TNF-α mRNA expression. Results: Visceral adiposity was significantly associated with serum concentrations of TNF receptor 1 (TNFR1), TNFR2, and vascular cell adhesion molecule-1 and adipose tissue expression of TNF-α and SOCS-3 (all P < 0.05). Insulin resistance as assessed by homeostasis model assessment was significantly associated with TNFR1, C-reactive protein, IL-6, and soluble intracellular adhesion molecule-1 (sICAM-1) (all P < 0.05). Etanercept significantly improved fasting glucose (treatment effect vs. placebo over 6 months, −10.8 ± 4.4%, P = 0.02). Etanercept also increased the ratio of high molecular weight adiponectin to total adiponectin (+22.1 ± 9.2% vs. placebo, P = 0.02), and decreased levels of sICAM-1 (−11 ± 2% vs. placebo, P < 0.0001). In contrast, body composition, lipids, C-reactive protein, and IL-6 were unchanged after 6 months. Conclusions: Prolonged therapy with etanercept improved fasting glucose, increased the ratio of high molecular weight to total adiponectin, and decreased sICAM-1 in obese subjects with abnormal glucose homeostasis and significant subclinical inflammation.

scholarly journals Changes in Serum High-Molecular-Weight Adiponectin Levels in Critically Ill Children with Systemic Inflammatory Response Syndrome

2016 ◽  
Vol 3 (1) ◽  
pp. 166-170
Author(s):  
Peteris Tretjakovs ◽  
Linda Rautiainena ◽  
Gita Krievina ◽  
Antra Jurka ◽  
Ilze Grope ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Systemic Inflammatory Response Syndrome ◽  
Inflammatory Response ◽  
High Molecular Weight ◽  
Systemic Inflammatory Response ◽  
Critically Ill Children ◽  
C Reactive Protein ◽  
High Molecular Weight Adiponectin ◽  
Icu Admission ◽  
Reactive Protein

Background: The aim of the study was to evaluate the effect of the systemic inflammatory response syndrome (SIRS) on serum high-molecular-weight adiponectin (HMWA) levels. Method: Twelve children with SIRS were enrolled in this study at the intensive care unit (ICU). Twelve age and sex matched healthy subjects were selected as controls. Serum HMWA, interleukin-6 (IL-6), C-reactive protein (CRP), and procalcitonin (PCT) levels were determined after 2 hours and 24 hours, and on the day of discharge which was on the average 9.4 days after ICU admission. Results: 2 hours after admission to the ICU, the patients had significantly decreased serum HMWA levels compared with healthy controls (P < .001). 24 hours after the admission, the patients did not have any significant changes in their HMWA levels, however on the day of discharge, on average 9.4 days after hospital admission, a significant increase was observed (P < .05). After the treatment, there was a decrease in serum PCT, IL-6 and CRP levels. The only variable that was decreased 24 hours after the ICU admission was PCT (P < .05). A negative correlation was found between serum HMWA and PCT levels, and between HMWA and CRP (P < .05 and P < .01), however no correlation was found between HMWA and IL-6. Conclusion: In SIRS we observed a marked reduction in serum HMWA concentrations and a profound increase in IL-6, PCT, and CRP levels. A significant relationship between serum HMWA and PCR and CRP levels was evident.

Sign in / Sign up

Export Citation Format

Share Document